Real-world treatment patterns and clinical outcomes in patients with AML from 65 to 74 years unfit for first-line intensive chemotherapy in Japan - PubMed
5 hours ago
- #Elderly patients
- #Acute myeloid leukemia
- #Venetoclax
- Venetoclax (VEN) was approved in Japan in March 2021 for treating acute myeloid leukemia (AML).
- A retrospective study analyzed treatment patterns and outcomes in AML patients aged 65-74 years unfit for intensive chemotherapy, comparing pre-VEN and post-VEN cohorts.
- Post-VEN approval, VEN + azacitidine (AZA) became the most used initial regimen (56%).
- VEN + AZA showed comparable response rates (CR + CRi: 64.5%) and overall survival (median OS: 11.7 months) to r7 + 3, and superior outcomes to CAG or AZA monotherapy.
- Early mortality at 60 days was lower with VEN + AZA (3.2%) compared to other treatments.
- The study highlights a shift in treatment practices post-VEN approval, suggesting VEN + AZA as an effective option for older AML patients with adverse genetic features.